XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
  Memory
  Regeneration
  Stroke
  Brain Diseases
  Headache
  Spinal Cord Diseases
  Demyelinating Diseases
   Multiple Sclerosis
  Neurodegenerative Diseases
  Taste
  Trigeminal Neuralgia
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Multiple Sclerosis Channel
subscribe to Multiple Sclerosis newsletter

Latest Research : Neurosciences : Demyelinating Diseases : Multiple Sclerosis

   DISCUSS   |   EMAIL   |   PRINT
RPI-78M Decreases Progression of Multiple Sclerosis by Altering Gene Expression
Mar 3, 2005, 16:24, Reviewed by: Dr.

"RPI-78M had a significant affect on the genes in the cytokine pathway as well as the myelination pathway," commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI).

 
Nutra Pharma Corp.,a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its contract researchers, Eno Research and Development, Inc. (ERDI) have completed their analysis of a series of microarray studies with RPI-78M in the gene expression of cells from Multiple Sclerosis (MS) patients.

RPI-78M is the lead drug candidate of Nutra Pharma's minority holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS. ERDI measured the effect of RPI-78M on gene expression using cDNA microarray technology to identify any potentially unique changes in gene expression that may be caused by the therapy.

ERDI was contracted by Nutra Pharma to analyze immune cells and brain lesions of Multiple Sclerosis patients with and without the addition of RPI-78M. They measured the changes in gene expression that occurred with treatment.

After statistical evaluation of the data, ERDI found more than sixty genes with significant changes in expression as compared to the control. In analyzing the affected genes, at least thirty of them may have a specific role in the progression of the disease and symptoms of MS.

"RPI-78M had a significant affect on the genes in the cytokine pathway as well as the myelination pathway," commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI).

"The cytokine pathway genes play a role in marshaling the attack on the nervous system by immune cells. Since this is one of the principle pathways that lead to the forward progression of MS, it is notable that if these results were replicated in the patient population it may greatly reduce the severity of the disease" he continued.

"Additionally, genes responsible for repair and maintenance of the myelin sheathes of neurons were upregulated. MS patients have a loss of myelin, the insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves. This damage or loss of myelin can prevent nerve signals from being conducted, or can cause those signals to be conducted too slowly. The data from this study suggests that RPI-78M may aid the patient in reversing some of the damage caused to the myelin by their disease." ERDI will continue to study RPI-78M and its effects on gene expression as well as the drug's effects in histoculture experiments that may further elucidate its mechanism of action.

There has been a great deal of interest surrounding research in Multiple Sclerosis therapies. There are currently four drugs on the market for the treatment of the disease. A fifth drug, Tysabri, was voluntarily pulled from the marketplace earlier this week by the drug's manufacturers, Biogen-Idec and Elan.

"We are working diligently with ERDI to bring this information to the scientific community," commented Rik J Deitsch, Chief Executive Officer of Nutra Pharma. "We expect to present the data at related conferences and to seek publication of the finished work. These studies, when coupled with the positive results in the recently-completed animal model, create substantial evidence of the drug's effects against MS. We are currently seeking potential partners that should allow us to move into sanctioned human trials," he added.

Multiple sclerosis (MS) is an autoimmune disease in which the immune system, the body's principal defense against foreign substances such as bacteria, mistakenly attacks normal tissues of the central nervous system. It afflicts approximately 400,000 people in the United States and more than 2.5 million worldwide. Specifically, the disease results in damage to a fatty tissue called myelin that surrounds and protects nerve fibers, creating scarring (sclerosis) that interferes with the normal transmission of nerve impulses. This damage, in turn, leads to a variety of chronic and highly individual and unpredictable neurological symptoms, ranging from movement and balance problems to vision impairment.

The disease is largely caused by activation of a specific subset of the patient's own white blood cells, T-cells that then attack the myelin and are largely responsible for disease progression.
 

- Nutra Pharma Corp.
 

Nutra Pharma Corp.

 
Subscribe to Multiple Sclerosis Newsletter
E-mail Address:

 

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's minority-owned subsidiary, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's other holding Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

ReceptoPharm is a bio-pharmaceutical company developing proprietary therapeutic proteins for the treatment of several chronic, life-threatening viral, auto-immune and neuro-degenerative disorders, specifically including Rabies, HIV, and Myasthenia gravis (MG).

Eno Research and Development, Inc. (ERDI) is a full-service contract research organization located in Hillsborough, North Carolina, near Research Triangle Park. ERDI offers a wide range of pre-clinical development services to pharmaceutical, biotechnology, medical device, animal health and nutraceutical companies. The scientific staff of ERDI possess expertise in biotechnology, pharmacology, tumor biology, synthetic and analytical chemistry, in silico modeling of drug interaction/binding and rational drug design, as well as microarray technology and bioinformatics. With this expertise, ERDI can offer services ranging from lead discovery through New Drug Applications.


Related Multiple Sclerosis News

Cause of nerve fiber damage in multiple sclerosis identified
Fampridine may hold promise for treating Multiple Sclerosis
CNS can send out signals to invite autoimmune attacks
Natalizumab Re-approved for Relapsing Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for interferon beta 1b in Multiple Sclerosis
Systematic Review Questions Accuracy of MRI in Multiple Sclerosis
Statins could prove useful in treating MS
12.5 kda cystatin may generate first simple test for multiple sclerosis
Fatal flaw in natalizumab, multiple sclerosis drug, trial
Azathioprine reduces new brain inflammatory lesions in MS


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us